Friday, July 10, 2026

Patent intelligence · US

US 12209135

Anti-CD45 antibodies and conjugates thereof

granted A61KA61K2035/124A61K2039/505A61K35/28
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 12
Patent details — US 12209135
Jurisdiction
US
Status
granted
Grant date
Jan 28, 2025
Expiration
Jan 23, 2045
Applicant
Vor Biopharma Inc.
Claims
22
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K35/28
View on Google Patents ↗

Quick answer

US 12209135 (Anti-CD45 antibodies and conjugates thereof) is held by Vor Biopharma Inc.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Vor Biopharma Inc.
Grant date
Expiration
Claims
22
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K35/28, A61K47/6803, A61K47/68035

More from Vor Biopharma Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12403200

    Methods and compositions for treating autoimmune diseases

    Vor Biopharma Inc. · Expires Aug 28, 2045

    granted
  2. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Expires May 1, 2045

    granted
  3. US 12251403

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Expires Mar 13, 2045

    granted
  4. US 11975029

    Compositions and methods for inhibition of lineage specific proteins

    Vor Biopharma Inc. · Expires May 2, 2044

    granted
  5. US 11903973

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Expires Feb 15, 2044

    granted
  6. US 11571445

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Expires Feb 2, 2043

    granted
  7. US 11559551

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Expires Jan 19, 2043

    granted

Frequently asked questions

What is US patent 12209135?

US 12209135 (Anti-CD45 antibodies and conjugates thereof) is held by Vor Biopharma Inc.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12209135?

Vor Biopharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 12209135 expire?

Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.